




Supplementary Figure 1. TCRs were successfully transduced into human T cells. TCR transduction rates were determined by staining of the mouse TCR β constant chain and subsequent analysis by flow cytometry. Mock transduced cells are untransduced with an empty virus, 14/35 TCR-transduced T cells serve as a positive control targeting CDK4R24L mutation. Percentages displayed are based on pregated CD3⁺ lymphocytes.




Supplementary Figure 2. Recombinant CDK4R24L and HLA-A*02:01 expression in human melanoma cell lines. (A) GFP intensities of melanoma cell lines after retroviral transduction with CDK4R24L full-length cDNA measured by flow cytometry. Control cells were representative examples of untransduced, GFP negative Mel55 cells. (B) The HLA-A*02:01 negative cell line Mel085 was retrovirally transduced with HLA-A*02:01 (Mel085-A2). Expression was confirmed by flow cytometry.



Supplementary Figure 3. Rapid amplification of mutant Rac2- but not Rac1-specific TCR gene-modified T cells upon recognition of Rac1P29S⁺ tumor cells *in vivo*. (A) 1×10^6 MC703-FSG cells were injected into HHDxRag^{-/-} mice. Mutant Rac1/2-specific T cells were injected (arrow) at an average tumor size of 322 mm^3 ($n=4$, 22894-Rac2, red lines), 331 mm^3 ($n=4$, 5934-Rac1, blue lines) and 345 mm^3 ($n=3$, 14/35-CDK4, black lines), respectively. One mouse did not receive T cells and served as negative control (grey line). Standard deviation (SD) is shown in D. (B) Mutant Rac2- but not Rac1-specific TCR gene-modified T cells show rapid amplification upon recognition of Rac1P29S⁺ FSG-GFP tumor cells. TCR 22894, 5934 and 14/35-transduced T cells were identified by staining with anti-human V β 22, V β 9 and V β 1 antibodies, respectively, and number of CD8⁺/huTCR⁺ T cells within the adoptively transferred CD3⁺/huTCR⁺ T cells was calculated. Numbers give percentage of CD3⁺/huV β ⁺ T cells, a representative FACS plot of each treatment group is shown. (C), (D) Standard deviation (SD) in growth curves of MC703-FSG cells injected into HHDxRag^{-/-} mice after T cell treatment (ATT) as shown in Figure 3B and Supplementary Figure 3A, respectively. Tumor rejection was compared at the indicated time point using two-way ANOVA.



Supplementary Figure 4. Recognition pattern of TCRs determined by alanine scan. (A-C) TCR-transduced human CD8 T cells were co-cultured with T2 cells that were loaded with mutant Rac1/2 peptide containing single alanine exchanges at 10^{-9} M (black bars) and 10^{-5} M (grey bars). After overnight incubation, IFN γ was measured in the supernatant. An amino acid was rated as TCR recognition site when the response to the respective alanine exchanged peptide was less than 50% as compared to the unchanged Rac1/2 peptide. **(D)** TCR-transduced human CD8⁺ T cells were co-cultured with T2 cells that were loaded with GNAZ (AAA) peptide. **(E)** TCR-transduced mouse CD8⁺ T cells were co-cultured with MC703 cells that were transduced to express a GNAZ triple 35mer. Cells were loaded with 10^{-6} M GNAZ peptide as a positive control. Mutant CDK4 14/35-TCR transduced T cells served as a negative control. **(F)** TCR-transduced human CD8⁺ T cells were co-cultured with HepG2 and SH-SY5Y-A2 cell lines endogenously expressing GNAZ. Cells were loaded with 10^{-6} M GNAZ peptide as a positive control. **(G)** TCR-transduced human CD8⁺ T cells were co-cultured with T2 cells that were loaded with Nibrin (FRI) peptide. PMA and Ionomycin (P/I) stimulation served as a positive control. The experiment was performed two times with similar results and graphs represent means of triplicate cultures \pm SD.



Supplementary Figure 5. No alloreactivity of mutant Rac1/2 TCR-transduced human T cells. (A-C) TCR-transduced CD8⁺ human T cells (A: 22894-Rac2, B: 5934-Rac1, C: A12B20-Rac1) were co-cultured with a panel of EBV-transformed lymphoblastoid B cell lines (LCLs) expressing different MHC class I molecules (Supplementary Table 1). After overnight incubation IFN γ was measured in the supernatant. A2 positive LCLs are shown with and without peptide at a concentration of 10⁻⁶ M. PMA and Ionomycin (P/I) stimulation served as positive control. The results are representative of two independent experiments performed with PBLs from different donors.

Supplementary Table 1. List of LCL cell lines.

B-LCL	HLA - A*		HLA - B*		HLA - C*	
SPO	02:01		44:02		05:01	
Bello	02:02	11:01	41:01	52:01	12:02	17:01
LCLW02	02:01	26:01	38:01	44:02	05:01	12:03
LCLW03	02:01	23:01	15:01	58:01	03:04	07:01
TAB089	02:07		46:01		01:02	
WT49	02:05:01		58:01:01		07:18	
XLI-ND	02:10	30:01	13:02	40:06:01:01	06:02	08:01
KLO	02:08	01:01:01:01	08:01:01	50:01:01	07:01:01:01	06:02:01:02
BSM	02:0101		15:010101		03:04:01	
KE	02:01	29:02	44:03	44:05	02:02	16:01
DJS	02:01	03:01	35:01	37:02	04:01	06:02
WT24	02:01:01		27:05:02		02:02:02	
JY	02:01		07:02		07:02	
KAS011	01:0101		37:01		06:02	
BM14	03:01		07:02		07:02	
MT14B	31:01		40:01		03:04	
SA	24:02:01:01		07:02:01		07:02	
HOR	33:0301		44:03:01		14:03	
TISI	24:02:01:01		35:08		04:01	
WIN	01:01		57:01:01		06:02	
KAS116	24:02:01:01		51:01		12:03	
DUCAF	30:02		18:01		05:01	
AMAI	68:02		53:01		04:01	
VAVY	01:01		08:01		07:01	
WT47	32:01		44:02		05:01	
LCLW01	03:01	24:02	15:01	35:01	03:03	04:01